Synovial Fibroblast 1: Secretion response of primary human synovial fibroblast samples from one healthy and one rheumatoid arthritis donor to a panel of 10 stimuli and 10 small molecule inhibitors - Dataset (ID:20233)
- Detail
- Small Molecules Studied
- Primary Cells Studied
- Proteins Studied
- Unclassified Perturbagens Studied
- Data Columns
- Results
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | Protein Stimulus | Other Stimulus | Stimulus Concentration | Stimulus Conc Unit | ExpPlate | Measured Protein | Measured Protein MFI (a.u.) | Bead Count |
|---|---|---|---|---|---|---|---|---|---|---|---|
| N2586 | PD184352 | 0.1 | uM | Adiponectin | 5 | ng/mL | 3 | IL-10 | 79.0 | 69 | |
| N2586 | Lestaurtinib | 0.3 | uM | Adiponectin | 5 | ng/mL | 3 | IL-10 | 88.5 | 58 | |
| N2586 | Ruxolitinib | 0.3 | uM | Adiponectin | 5 | ng/mL | 3 | IL-10 | 99.5 | 64 | |
| N2586 | Tofacitinib | 0.3 | uM | Adiponectin | 5 | ng/mL | 3 | IL-10 | 87.0 | 67 | |
| N2586 | IKK16 | 2.0 | uM | Adiponectin | 5 | ng/mL | 3 | IL-10 | 105.0 | 50 | |
| RA2159 | IGF-I | 100 | ug/mL | 3 | IL-10 | 64.0 | 68 | ||||
| RA2159 | PD184352 | 0.1 | uM | IGF-I | 100 | ug/mL | 3 | IL-10 | 67.5 | 68 | |
| RA2159 | Lestaurtinib | 0.3 | uM | IGF-I | 100 | ug/mL | 3 | IL-10 | 64.0 | 51 | |
| RA2159 | Ruxolitinib | 0.3 | uM | IGF-I | 100 | ug/mL | 3 | IL-10 | 66.0 | 63 | |
| RA2159 | Tofacitinib | 0.3 | uM | IGF-I | 100 | ug/mL | 3 | IL-10 | 63.0 | 72 | |
| RA2159 | IKK16 | 2.0 | uM | IGF-I | 100 | ug/mL | 3 | IL-10 | 69.0 | 59 | |
| RA2159 | 3 | IL-10 | 74.0 | 54 | |||||||
| N2586 | IGF-I | 100 | ug/mL | 3 | IL-10 | 76.5 | 56 | ||||
| N2586 | PD184352 | 0.1 | uM | IGF-I | 100 | ug/mL | 3 | IL-10 | 75.0 | 47 | |
| N2586 | Lestaurtinib | 0.3 | uM | IGF-I | 100 | ug/mL | 3 | IL-10 | 71.5 | 50 | |
| N2586 | Ruxolitinib | 0.3 | uM | IGF-I | 100 | ug/mL | 3 | IL-10 | 112.0 | 64 | |
| N2586 | Tofacitinib | 0.3 | uM | IGF-I | 100 | ug/mL | 3 | IL-10 | 89.0 | 63 | |
| N2586 | IKK16 | 2.0 | uM | IGF-I | 100 | ug/mL | 3 | IL-10 | 94.0 | 55 | |
| N2586 | 3 | IL-10 | 75.0 | 53 | |||||||
| RA2159 | EGF | 100 | ng/mL | 3 | IL-10 | 73.5 | 58 | ||||
| RA2159 | PD184352 | 0.1 | uM | EGF | 100 | ng/mL | 3 | IL-10 | 76.0 | 40 | |
| RA2159 | Lestaurtinib | 0.3 | uM | EGF | 100 | ng/mL | 3 | IL-10 | 60.0 | 55 | |
| RA2159 | Ruxolitinib | 0.3 | uM | EGF | 100 | ng/mL | 3 | IL-10 | 75.0 | 50 | |
| RA2159 | Tofacitinib | 0.3 | uM | EGF | 100 | ng/mL | 3 | IL-10 | 34.0 | 61 | |
| RA2159 | IKK16 | 2.0 | uM | EGF | 100 | ng/mL | 3 | IL-10 | 59.5 | 48 |